66500-55-8

Basic information

• Product Name: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid
• Synonyms: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid;EOS-61698;cyclohexanone-4-carboxylic acid ethyleneacetal
• CAS NO: 66500-55-8
• Molecular Formula: C₉H₁₄O₄
• Molecular Weight: 186.20506
• Mol File: 66500-55-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid(66500-55-8)
• EPA Substance Registry System: 1,4-Dioxaspiro[4.5]decane-8-carboxylic acid(66500-55-8)

Safety Data

• Hazardous Substances Data: 66500-55-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry Research:
1,4-Dioxaspiro[4.5]decane-8-carboxylic acid is used as a research compound for understanding molecular structures and reaction dynamics in organic chemistry. Its unique spiro functional group provides insights into the behavior of such compounds in various chemical reactions.
Used in Drug Development:
1,4-Dioxaspiro[4.5]decane-8-carboxylic acid is used as a building block in the synthesis of larger, more complex molecules for drug development. Its incorporation into these molecules can potentially lead to the creation of new pharmaceutical compounds with novel therapeutic properties.
Used in Chemical Synthesis:
1,4-Dioxaspiro[4.5]decane-8-carboxylic acid is used as an intermediate in the synthesis of various chemical compounds. Its unique structure allows for the formation of new bonds and the creation of a wide range of chemical products, making it a valuable component in the field of chemical synthesis.

Upstream product

• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 69947-09-7 1,4-dioxaspiro<4.5>decane-8-carbonitrile 
• 107-21-1 ethylene glycol 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 

Downstream Products

• 108720-11-2 1,4-dioxa-spiro[4.5]decane-8-carboxylic acid-(3,4-dimethoxy-phenethylamide) 
• 132292-26-3 1-carboxy-1'-hydroxy-1,1':4',1''-tercyclohexan-4-one ethylene ketal 

Relevant articles and documents

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

INHIBITORS OF EZH2

The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.

Azabenzimidazole derivative having AMPK-activating activity

Disclosed is a compound which is useful as an AMPK activator. A compound represented by formula: or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, or substituted or unsubstituted alkyl, R1, R2 and R3 are each independently hydrogen, halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl or the like, with the proviso that R1, R2 and R3 are not simultaneously hydrogen, X is a single bond, —S—, —O—, —NR5—, —C(═O)— or the like, R5 is hydrogen, or substituted or unsubstituted alkyl, Y is substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted heterocyclyl or the like.

INHIBITORS OF EZH2

The present invention relates to compounds that inhibit activity of the histone lysine N-methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.

FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.

PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS

The present invention provides methods for inhibiting mTOR using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with mTOR using such compounds.

Spirocyclic nitriles as protease inhibitors

The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.